Thanks for posting a link to a good early overview.

From the article.

Quote:

---

elevated inflammatory cytokines, as well as clotting disorders

---

Leronlimab resets that.

Quote:

---

Nath speculates that, among COVID-19 survivors, “leaky vessels might allow the entry of toxic blood compounds into the brain that lead to permanent or long-term symptoms.”

---

Inflammatory conditions increase leakage in the blood brain barrier. Leronlimab can fix that.

Quote:

---

Liam O’Mahony, an immunologist at APC Microbiome Ireland, a research center based at University College Cork, is publishing a study showing that inflammatory markers, such as interleukin (IL)-6, tumor necrosis factor (TNF)-α, and C-reactive protein, were elevated in blood plasma... His research also shows that polarizing markers of adaptive immunity, including IL-17 and IL-4, are elevated in long-COVID.

---

Leronlimab downregulates those.

Quote:

---

Finally, scientists are investigating the possibility that long-COVID symptoms might arise in some cases from autoantibodies attacking the body’s own cells.

---

Leronlimab can reverse the overreaction of autoantibodies.

They list some potential drugs for long-COVID treatment including leronlimab. But those drugs treat narrow symptomologies and leronlimab will do what they all do individually.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8277229/